Day 1: Sunday, December 7, 2025
SESSION 1: Prospects for global elimination of viral hepatitis and treatment for HCC
Plenary lecture: Progress toward hepatitis B and C elimination
Homie Razavi - Centers for Disease Analysis Foundation, USA
Hepatitis elimination is not achievable without a SEARCH
Miriam Levy - Liverpool Hospital and UNSW, Australia
Special Lecture: Checkpoint therapy for hepatocellular carcinoma – 2025 and beyond
George Lau - Humanity and Health Medical Center, Hong Kong, China
Day 2: Monday, December 8, 2025
William H. Prusoff HEP-DART Lifetime Achievement Award lecture
SESSION 2: Challenges for MASH and Perspectives on viral hepatitis
Plenary Lecture: Understand the consequences of MASH on HCV/ HBV natural history
Norah Terrault - University of Southern California, USA
Updates in guidance and approach to HBV and HCV in pregnant people - critical population for our path to HBV/HCV Elimination
Tatyana Kushner - Weill Cornell Medicine, USA
Impact and importance of involving people with lived experience and community groups in drug development processes
Laura Malone - World Hepatitis Alliance
Oral Abstract Session I
Piloting a mobile, adaptive street medicine clinic for treating hepatitis C among unsheltered homeless individuals in Central Florida
Karla Ganley - University of Florida Street Medicine Program, USA
From commitment to cure: expanding access to Hepatitis C treatment through Ghana’s STOP Hep C project
Robert Lewis -
SESSION 3: Hepatitis B basic science, immunology, and therapeutics (Hepatitis B Foundation sponsored session)
Plenary Lecture: Basic research for hepatitis B infections
Barbara Testoni - Lyon University, France
Merging WHO, EASL, AASLD and the China HBV Guidelines
Markus Cornberg - Medical School Hannover, Germany
The future of IFN-based therapies for HBV cure
Lefteris Michailidis - Emory University, USA
Taking HBV prevention and cure to Africa
Catherine Freeland - HepB Foundation, USA
Oral Abstract Session II
Discovery of HS-83128: An orally bioavailable, liver-targeted dihydroquinolizinone with In Vivo efficacy against HAV and HBV
Yanming Du - Baruch S. Blumberg Institute, USA
Hepatic TDAG51 deficiency attenuates MCD diet-induced liver pathology through dampened UPR signaling
Tamana Yousof - University of Alberta, Canada
Efficacy of E-CFCP, a novel long-acting anti-HBV nucleoside analog, on chronic Hepatitis B in humanized liver chimeric mice
Hioraki Mitsuya - Japan Institute for Health Security, Tokyo, Japan, National Institutes of Health, USA
Identification and mechanistic investigations of first-in-class hydrophobic tagging-based degraders targeting HBV Core Protein
Peng Zhan - Shandong University, China
HBV Reactivation Associated with CAR-T Therapy: Recommendations for Prompt and Prolonged Antiviral Prophylaxis
Adrian Di Bisceglie - Saint Louis University, USA
Day 3: Tuesday, December 9, 2025
SESSION 4: New advances in HBV Cure
Plenary Lecture: HBV cure - what are the risks and rewards
Ed Gane - University of Aukland, New Zealand
Novel antivirals for HBV functional cure
Mark Sulkowski - Johns Hopkins University, USA
In vivo efficacy of a CAM from the magnitude of the first phase decline in HBV RNA
Alan Perelson - Los Alamos National Laboratory, USA
Special Lecture: Update on biomarkers of HBV disease
Man Fung Yuen - Hong Kong University, HK
SESSION 5: Leaping forward for long-acting injectables and vaccines
Plenary Lecture: Long-acting injectables for HBV & HCV: a key to elimination
Charles Flexner - Johns Hopkins University, USA
HBV vaccines in people living with HIV and current HCV vaccine efforts
Andrea Cox - Johns Hopkins University, USA
Using CHIM (Controlled Human Infection Model) to accelerate HCV vaccine development
Jordan Feld - UNH, Canada
SESSION 6: Industry session: Getting closer to HBV and MASH curative modalities
Madrigal
TBA
Gilead
Jenny Svarovkaia - Gilead, USA
GSK
Charlene Prazma - GSK, United Kingdom
Precision
Emily Harrison - Precision Biosciences, USA
Vir Biotechnologies
Todd Correll - Vir Biotechnologies, USA
Rapid, profound and durable antiviral effects in treatment-naïve or currently-not-treated subjects with chronic hepatitis B virus infection that received 300 mg pevifoscorvir sodium monotherapy for 96 weeks
Larry Blatt - Aligos, USA
Day 4: Wednesday, December 10, 2025
SESSION 7: Advancements in MASH and MASLD
Plenary talk: MASLD and cardiovascular disease
Laurence Sperling - Emory University, USA
Reasonably likely surrogate endpoint for MASH - road to validation
Veronica Miller - University of California, Berkeley, USA
Special Lecture: GLP-1s and combination— the impact of these drugs cannot be understated and will influence future drug development for MASLD/MASH
Arun Sanyal - Virginia Commonwealth University, USA
SESSION 8: Advances in Hepatitis D therapeutics
Plenary Lecture: The HDV epidemic – is the problem bigger or smaller than we think and will this affect the treatment landscape?
Pietro Lampertico - University of Milan, Italy
Emerging therapies for hepatitis D and long-term outcomes of antiviral treatment in chronic viral hepatitis
Tarik Asselah - Hospital Beaujon, France
Oral Abstract Session III
The effectiveness of Bulevirtide monotherapy is similar in chronic Hepatitis Delta patients with and without cirrhosis results from the prospective multicenter D-Shield Study
Maria Paola Anolli, University of Milan, Italy
Three years of Bulevirtide monotherapy in patients with HDV-related compensated cirrhosis: Virological outcomes and safety data from the retrospective multicenter European study (SAVE-D)
Elizabetta Degasperi - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy
Delta viruses spread through viral Trojan Horse
Karim Majzoub - Centre National de la Recherche Scientifique (CNRS) / Institut de Génétique Moléculaire de Montpellier (IGMM), France
SESSION 9: Advances in Hepatocellular Cancer Treatment
Plenary Lecture: HCC: the path to molecular targeting: HCC is a "drugable" cancer
Richard Finn - UCLA, USA
Oral Abstract Session IV
From viral hepatitis to metabolic dysfunction: Nationwide inpatient outcomes of HCV- and MASLD-Related Hepatocellular Carcinoma, 2020–2022
Muhammad Haris Latif - SSM St Mary's Hospital, USA
Microbial biotherapeutic metabolite alleviates liver injury by restoring lipid metabolism and gut-liver axis homeostasis via PPARα
Satya Dandekar - University of California Davis, USA
IB-001 is a partial agonist of the type I interferon pathway that exhibits potent antiviral activity against HBV and HDV with the potential for an improved safety profile
Carey Hwang - IntegerBio, USA
The HDAg acidic cluster mimicking the host histones nucleosome acidic patch is crucial for viral replication
Massimo Levrero - Inserm, France
Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-β agonist ALG-055009 was administered in combination with incretin receptor agonists
Xuan Luong - Aligos Therapeutics, USA
Histotripsy, a novel non-invasive therapy for liver tumors: An outpatient medical management experience
Tarik Hassanein - Southern California Liver Centers, USA
BUSINESS DISCUSSION SESSION: (Non-CME)
Business of therapeutics for hepatitis and liver diseases
Geoff Meacham - Citi Bank, USA
Tavi Yehudai - Trails Edge Capital Partners, USA
Day 5: Thursday, December 11, 2025
SESSION 10: Alternative approaches for cure
Plenary Lecture: Gene editing and epigenetic modification for HBV cure
Fabien Zoulim - Lyon University, France
Strengths and weaknesses of the HBV ribonuclease H as a drug target
John Tavis - Washington University in St. Louis, USA
Curing HBV by safely modifying the immune system
Adam Gehring - UHN Toronto, Canada
Oral Abstract Session V
ROR⍺ controls hepatocyte extracellular vesicle loading of the immunomodulatory lncRNA MALAT-1
Rabindra Tirouvanziam - Emory University, USA
Pregnancy outcomes in women with hepatitis C: A Nationwide Propensity-Matched Analysis
Yassine Kilani - Saint Louis University School of Medicine, USA
Patient-specific transcriptomic changes in paired HCV liver biopsies before and after DAA therapy
Kellen Hanning - University of Texas Medical Branch, USA
Mathematical modeling suggests that undetectable HCV RNA at days 7 or 14 of glecaprevir-pibrentasvir therapy could identify individuals with recent HCV for shorter treatment duration
Harel Dahari - Loyola University, Chicago
Final Session
2025 & Beyond: Sea of change and navigating turbulent times
Robert Gish - Antivirals & viral diseases
Adrian Di Bisceglie - MASH & liver diseases